Ladenburg Thalmann Expects Postive FDA Panel for Northera

According to a recent research report, Ladenburg Thalmann is expecting a positive FDA panel for Chelsea Therapeutics'

Northera on February 23, 2012. In the report, Ladenburg Thalmann said, “In our view, the totality of the Northera package supports a positive risk-benefit assessment for the drug. Therefore, we are positive on the potential for Northera's approval and a positive vote in the upcoming FDA cardiovascular and renal drugs advisory committee meeting (February 23rd). Having said that, the clinical development/regulatory history of Northera has been circuitous which is conducive to generating questions and diverse points of view. For this reason, despite being optimistic about the outcome of the panel and final approval, we would not be surprised if the panel's discussion becomes contentious at times.” Ladenburg Thalmann reiterates its Buy rating and $8 PT on Chelsea Therapeutics, which is currently trading at $5.09.